In the recent SEC filing::
"6. WE DEPEND ON PATENTS AND PROPRIETARY RIGHTS, WHICH MAY OFFER ONLY LIMITED PROTECTION AGAINST POTENTIAL INFRINGEMENT. IF WE ARE UNABLE TO PROTECT OUR PATENTS AND PROPRIETARY RIGHTS, OUR BUSINESS, FINANCIAL CONDITION AND RESULTS OF OPERATIONS WILL BE HARMED."
This statement precedes your mention, Dan, about the current state of the Michigan patent suit, and Commonwealth is trying to get...
"(ii) an injunction against Advanced Viral from further attempts to use, market or assert any claims of ownership over any broad/exclusive rights in Reticulose, or the use, publication or disclosure of information regarding Reticulose;"
Of course we ADVR investors hope that this claim will be rejected by the courts and ADVR can move unincumbered by this kind of legal claim.
That said, does anyone know (or find out) if this suit is in any way delaying any of the ongoing drug application processes? Does this suit have to be settled BEFORE any IND can be filed? Will this suit impact in any way the possibility of attracting investors, possible partners and other integral personnel to the company??
These questions are ugly to raise, and I wish they weren't there to look at. But reality makes it imperative (to me) to want some real answers.
KAKALAK has suggested some kind of sunshine statement from ADVR, indication the actual place the company is in it's trek toward success. I agree. |
